New Report From The NEJM On Clinical Trial Reporting Further Tarnishes Biopharma’s Image

Forbes, 11 March 2015
Author: John LaMattina
“The biopharmaceutical industry is a pretty big target these days. Now a new paper entitled ‚ÄúCompliance with Results Reporting at” published in The New England Journal of Medicine will further fuel the storm. For anyone concerned about transparency in clinical trial results, the findings were pretty disappointing.”
Find article here.